Related Experiment Video
Updated: Jul 11, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Efficacy of vitamin E in children with immunotolerant-phase chronic hepatitis B infection
Bunyamin Dikici1, Abdullah Dagli, Hasan Ucmak
1Department of Pediatrics, Abant Izzet Baysal University, Duzce Medical Faculty, Duzce, Turkey. bdikici@hotmail.com
Insights
This study found vitamin E did not improve liver enzymes or viral load in children with chronic hepatitis B virus (CHB) infection. Further research into other immunomodulators is recommended for this patient group.
Area of Science:
- Hepatology
- Pediatric Gastroenterology
- Immunology
Background:
- Chronic hepatitis B virus (CHB) infection affects children worldwide.
- The immunotolerant phase is characterized by high viral replication and normal liver enzymes.
- Effective treatment strategies for this phase are limited.
Purpose of the Study:
- To investigate the efficacy of vitamin E in children with immunotolerant-phase CHB infection.
- To evaluate the impact of vitamin E on serological, virologic, and biochemical markers.
- To determine if vitamin E offers a beneficial effect in this pediatric population.
Main Methods:
- A prospective, randomized study involving 58 children with immunotolerant CHB.
- Group 1 received vitamin E (100 mg/day) for 3 months; Group 2 (control) received no medication.
- Outcomes assessed included alanine transaminase (ALT) levels and hepatitis B virus (HBV)-DNA load at baseline, 3 months, and 6 months post-therapy.
Main Results:
- No significant changes in mean ALT values or HBV-DNA load were observed in the vitamin E group compared to the control group.
- No statistically significant differences in ALT or HBV-DNA levels were found between the two groups at any time point.
- Hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) clearance or seroconversion were not observed in either group.
Conclusions:
- Vitamin E demonstrated no beneficial effect in children with immunotolerant CHB infection.
- This is the first study to investigate vitamin E's efficacy in this specific pediatric CHB phase.
- Future research should explore alternative immunomodulatory protocols for treating immunotolerant CHB in children.
Background:
The purpose of the present paper was to investigate the efficacy of vitamin E in children with immunotolerant-phase chronic hepatitis B virus (CHB) infection.
Methods:
Fifty-eight immunotolerant children were prospectively and randomly recruited into two groups. Group 1 (study group) included 30 patients who received vitamin E at a dose of 100 mg/day throughout 3 months; group 2 (control group) contained 28 patients who did not receive any medication. Comparison of serological, virologic, and biochemical response ratios were done at the end of the therapy and after 6 months of vitamin E discontinuation.
Results:
Mean alanine transaminase (ALT) values in group 1 at the beginning of the therapy, 3 months after the therapy initiation and 6 months after discontinuation were 30.4 +/- 7.3 IU/L, 31.3 +/- 7.8 IU/L and 32.1 +/- 8.5 IU/L, respectively. The mean hepatitis B virus (HBV)-DNA load of group 1 at onset, and at the third and ninth months of the treatment were 3106 +/- 718 pg/mL, 3530 +/- 137 pg/mL and 3364 +/- 1246 pg/mL, respectively. These changes in both ALT and HBV-DNA values did not reach significant levels (P > 0.05). In group 2, mean ALT values at the beginning of therapy, and at the third and ninth months were 28.0 +/- 1.8 IU/L, 34.6 +/- 8.1 IU/L, and 34.1 +/- 7.0 IU/L, respectively (P > 0.05), and mean viral load of HBV-DNA was 4227 +/- 1435 pg/mL, 3368 +/- 2673 pg/mL, and 3018 +/- 2814 pg/mL, respectively (P > 0.05). There was no statistically significant difference between group 1 and group 2 at the third and ninth months in the mean ALT values and viral load of HBV-DNA (P > 0.05). Hepatitis B s antigen and hepatitis B e antigen clearance or hepatitis B s antibody and hepatitis B e antibody seroconversion were not observed in either group.
Conclusion:
As a first study investigating the effect of vitamin E in children with immunotolerant CHB infection, no beneficial effect could be demonstrated. Different immunomodulator protocols should be considered for future investigations.
Related Concept Videos
Hepatitis
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Viral Hepatitis I: Introduction
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Pharmacokinetics in Pediatric Patients: Drug Excretion
Inhibitors of Viral Protein Synthesis
